Shares of Illumina (ILMN), a leading genomics company, surged 7.05% in Thursday's trading session following the release of its impressive third-quarter results and an optimistic outlook for the full year. The company's performance significantly exceeded analyst expectations, demonstrating strong growth in key areas and improved financial metrics.
Illumina reported Q3 revenue of $1.084 billion, surpassing the analyst consensus estimate of $1.065 billion. The company's adjusted earnings per share (EPS) came in at $1.34, handily beating the expected $1.17. This represents a substantial 17.54% increase from the $1.14 per share reported in the same period last year. Additionally, Illumina's adjusted net income of $206 million outperformed analyst projections of $182.2 million.
The robust quarterly performance was primarily driven by growth in the clinical market, Illumina's largest segment, as highlighted by CEO Jacob Thaysen. The company also reported a return to growth outside of China, indicating successful execution of its strategic initiatives aimed at achieving long-term targets. Furthermore, Illumina launched new technologies, including a 5-base solution and Constellation mapped read technology, enhancing its genomic insights capabilities. In a show of confidence, the company repurchased 1.2 million shares for $120 million during the quarter.
Looking ahead, Illumina raised its fiscal year 2025 guidance, further fueling investor optimism. The company now expects non-GAAP EPS in the range of $4.65 to $4.75, up from its previous estimate of $4.45 to $4.55. While Illumina anticipates a slight decline in constant currency revenue for the full year, projecting a range of -1.5% to -0.5%, the improved earnings outlook and strong quarterly results have clearly overshadowed this minor concern in investors' minds.
The market's enthusiastic response to Illumina's results reflects growing confidence in the company's ability to navigate challenges and capitalize on growth opportunities in the genomics sector. As Illumina continues to innovate and expand its market presence, investors will be closely watching for sustained momentum in the coming quarters.